Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Shambavi Richard, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology) with the Center of Excellence for Multiple Myeloma. She sees multiple myeloma patients at the Ruttenberg Treatment Center at The Mount Sinai Hospital and also at The Blavatnik Family - Chelsea Medical Center. Dr. Richard applies a multi-disciplinary approach for each of her patients alongside her collaborative team members.
Dr. Richard did her fellowship training in hematology and medical oncology at Montefiore medical center in the Bronx, New York, and then did a year of fellowship in hematopoietic stem cell transplantation at Mount Sinai Hospital in new York.
In practice for more than 15 years, Dr. Richard has extensive experience in transplantation for multiple myeloma. She is a principal investigator and is involved in several phase 1, phase 2, and first in human clinical trials in multiple myeloma with a focus on several novel therapies, including antibody, immunotherapy, and targeted therapy treatment approaches. Dr. Richard will be leading the CART and Cellular therapy program for myeloma at Mount Sinai.
The Multiple Myeloma Program has played a pivotal role in the approval of several recent drugs that are now FDA approved for the treatment of multiple myeloma. Additionally, Dr. Richard leads a precursor clinic for multiple myeloma where she sees patients who have monoclonal gammopathies of uncertain significance (MGUS) and smoldering myeloma with a goal to prevent evolution to myeloma.